fluorouracil has been researched along with Proliferative Vitreoretinopathy in 28 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the efficacy of a combination of 5-fluorouracil and low-molecular-weight heparin (LMWH) to improve the outcome of surgery for established proliferative vitreoretinopathy (PVR)." | 9.11 | A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. ( Asaria, RH; Aylward, GW; Bunce, C; Charteris, DG; Groenewald, C; Wong, D, 2004) |
| "To assess the safety and efficacy of adjuvant combination therapy using 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) for prevention of proliferative vitreoretinopathy (PVR) after vitrectomy and retinal reattachment surgery." | 9.09 | Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial. ( Asaria, RH; Aylward, GW; Bunce, C; Charteris, DG; Khaw, PT; Kon, CH; Wong, D, 2001) |
| "To evaluate the efficacy of 5-fluorouracil polyactic acid microsphere in prevention of proliferative vitreoretinopathy (PVR)." | 7.73 | [Efficacy of 5-fluorouracil polyactic acid microsphere in prevention of proliferative vitreoretinopathy]. ( Bi, HS; Cui, Y; Wang, XR; Xie, XF; Zhang, JH, 2006) |
| "Three new N(1)-alkylcarbonyl-5-fluorouracil derivatives that are prodrugs of 5-fluorouracil (FU), one of them being a co-drug FU-retinoic acid (RA), were studied as potentially effective drugs against postsurgical proliferative vitreoretinopathy (PVR)." | 7.72 | Fluorouracil prodrugs for the treatment of proliferative vitreoretinopathy: formulation in silicone oil and in vitro release of fluorouracil. ( Jolimaître, P; Malet-Martino, M; Martino, R, 2003) |
| "To determine the potential of an intravitreal sustained release naproxen and 5-fluorouracil (NA/5-FU) codrug for the treatment of experimental proliferative vitreoretinopathy (PVR) in a model for trauma associated tractional retinal detachment (TRD)." | 7.72 | An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. ( Ashton, P; Cardillo, JA; Costa, RA; Farah, ME; Jorge, R; Kuppermann, B; Melo, LA; Mitre, J; Morales, PH, 2004) |
| "To determine the efficacy and pharmacokinetics of an intravitreal sustained-release triamcinolone acetonide and 5-fluorouracil (TA/5-FU) codrug in the treatment of experimental proliferative vitreoretinopathy (PVR)." | 7.70 | An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. ( Ashton, P; Chen, SN; Guo, H; Hainsworth, DP; Jaffe, GJ; Khawly, JA; Yang, CS, 1998) |
| "To determine the efficacy of a combination of 5-fluorouracil and low-molecular-weight heparin (LMWH) to improve the outcome of surgery for established proliferative vitreoretinopathy (PVR)." | 5.11 | A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. ( Asaria, RH; Aylward, GW; Bunce, C; Charteris, DG; Groenewald, C; Wong, D, 2004) |
| "To study the safety and efficacy of adjuvant combination therapy using 5-fluorouracil and heparin for prevention of proliferative vitreoretinopathy (PVR) during vitrectomy for retinal detachment surgery." | 5.11 | [Prevention of proliferative vitreoretinopathy using 5-FU heparin: clinical tolerance and efficacy]. ( Bonnel, S; Laroche, L; Morel, C; Poisson, F; Sahel, JA; Scheer, S; Touzeau, O, 2005) |
| "To assess the safety and efficacy of adjuvant combination therapy using 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) for prevention of proliferative vitreoretinopathy (PVR) after vitrectomy and retinal reattachment surgery." | 5.09 | Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial. ( Asaria, RH; Aylward, GW; Bunce, C; Charteris, DG; Khaw, PT; Kon, CH; Wong, D, 2001) |
| "To analyse the cytotoxic and antiproliferative effect of methotrexate (MTX) and fluorouracil (5-FU) in vitro on fibroblasts, retinal pigment epithelial (RPE) and photoreceptor cells as an adjunct for reducing the incidence of proliferative vitreoretinopathy (PVR) after rhegmatogenous retinal detachment surgery." | 4.02 | Comparative cytotoxic and antiproliferative profile of methotrexate and fluorouracil on different ocular cells. ( Germann, A; Januschowski, K; Julich-Haertel, H; Rickmann, A; Schulz, A; Szurman, P; von Briesen, H, 2021) |
| "To evaluate the efficacy of 5-fluorouracil polyactic acid microsphere in prevention of proliferative vitreoretinopathy (PVR)." | 3.73 | [Efficacy of 5-fluorouracil polyactic acid microsphere in prevention of proliferative vitreoretinopathy]. ( Bi, HS; Cui, Y; Wang, XR; Xie, XF; Zhang, JH, 2006) |
| "Three new N(1)-alkylcarbonyl-5-fluorouracil derivatives that are prodrugs of 5-fluorouracil (FU), one of them being a co-drug FU-retinoic acid (RA), were studied as potentially effective drugs against postsurgical proliferative vitreoretinopathy (PVR)." | 3.72 | Fluorouracil prodrugs for the treatment of proliferative vitreoretinopathy: formulation in silicone oil and in vitro release of fluorouracil. ( Jolimaître, P; Malet-Martino, M; Martino, R, 2003) |
| " Macular relocation surgery involved phacoemulsification, vitrectomy, 360 degrees retinotomy, excision of choroidal neovascular membrane, and macular relocation using an infusion of 5-fluorouracil and low molecular weight heparin as adjuvant to prevent proliferative vitreoretinopathy." | 3.72 | Case selection in macular relocation surgery for age related macular degeneration. ( Briggs, M; Groenewald, C; Lancaster, E; Lenfestey, P; Li, KK; Lim, KS; Stanga, P; Wong, D, 2004) |
| "To determine the potential of an intravitreal sustained release naproxen and 5-fluorouracil (NA/5-FU) codrug for the treatment of experimental proliferative vitreoretinopathy (PVR) in a model for trauma associated tractional retinal detachment (TRD)." | 3.72 | An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. ( Ashton, P; Cardillo, JA; Costa, RA; Farah, ME; Jorge, R; Kuppermann, B; Melo, LA; Mitre, J; Morales, PH, 2004) |
| "To determine the efficacy and pharmacokinetics of an intravitreal sustained-release triamcinolone acetonide and 5-fluorouracil (TA/5-FU) codrug in the treatment of experimental proliferative vitreoretinopathy (PVR)." | 3.70 | An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. ( Ashton, P; Chen, SN; Guo, H; Hainsworth, DP; Jaffe, GJ; Khawly, JA; Yang, CS, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (14.29) | 18.2507 |
| 2000's | 12 (42.86) | 29.6817 |
| 2010's | 8 (28.57) | 24.3611 |
| 2020's | 4 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Schaub, F | 2 |
| Schiller, P | 2 |
| Hoerster, R | 2 |
| Kraus, D | 2 |
| Holz, FG | 1 |
| Guthoff, R | 1 |
| Agostini, H | 1 |
| Spitzer, MS | 1 |
| Wiedemann, P | 1 |
| Lommatzsch, A | 1 |
| Boden, KT | 1 |
| Dimopoulos, S | 1 |
| Bemme, S | 1 |
| Tamm, S | 1 |
| Maier, M | 1 |
| Roider, J | 1 |
| Enders, P | 1 |
| Altay, L | 1 |
| Fauser, S | 2 |
| Kirchhof, B | 2 |
| van Overdam, KA | 1 |
| Sebag, J | 2 |
| Yu, Z | 1 |
| Ma, S | 1 |
| Wu, M | 1 |
| Cui, H | 1 |
| Wu, R | 1 |
| Chen, S | 1 |
| Xu, C | 1 |
| Lu, X | 1 |
| Feng, S | 1 |
| Schulz, A | 1 |
| Rickmann, A | 1 |
| Julich-Haertel, H | 1 |
| Germann, A | 1 |
| von Briesen, H | 1 |
| Januschowski, K | 1 |
| Szurman, P | 1 |
| Felsch, M | 1 |
| Zarrouk, M | 1 |
| Sundaram, V | 2 |
| Barsam, A | 2 |
| Virgili, G | 2 |
| Chiquet, C | 1 |
| Rouberol, F | 1 |
| Khan, MA | 1 |
| Brady, CJ | 1 |
| Kaiser, RS | 1 |
| Wickham, L | 1 |
| Bunce, C | 3 |
| Wong, D | 4 |
| Charteris, DG | 3 |
| Zheng, H | 1 |
| Wang, Z | 1 |
| Wang, P | 1 |
| Liu, Y | 1 |
| Jiang, Z | 1 |
| Gao, Q | 1 |
| Moysidis, SN | 1 |
| Thanos, A | 1 |
| Vavvas, DG | 1 |
| Jolimaître, P | 1 |
| Malet-Martino, M | 1 |
| Martino, R | 1 |
| Stanga, P | 1 |
| Briggs, M | 1 |
| Lenfestey, P | 1 |
| Lancaster, E | 1 |
| Li, KK | 1 |
| Lim, KS | 1 |
| Groenewald, C | 2 |
| Cardillo, JA | 1 |
| Farah, ME | 1 |
| Mitre, J | 1 |
| Morales, PH | 1 |
| Costa, RA | 1 |
| Melo, LA | 1 |
| Kuppermann, B | 1 |
| Jorge, R | 1 |
| Ashton, P | 3 |
| Aylward, GW | 3 |
| Asaria, RH | 2 |
| Scheer, S | 1 |
| Morel, C | 1 |
| Poisson, F | 1 |
| Bonnel, S | 1 |
| Touzeau, O | 1 |
| Sahel, JA | 1 |
| Laroche, L | 1 |
| Bi, HS | 1 |
| Cui, Y | 1 |
| Zhang, JH | 1 |
| Wang, XR | 1 |
| Xie, XF | 1 |
| Creten, O | 2 |
| Spileers, W | 2 |
| Stalmans, P | 2 |
| Borhani, H | 1 |
| Peyman, GA | 1 |
| Rahimy, MH | 1 |
| Thompson, H | 1 |
| Berger, AS | 1 |
| Cheng, CK | 1 |
| Pearson, PA | 1 |
| Crooks, PA | 1 |
| Cynkowski, T | 1 |
| Cynkowska, G | 1 |
| Jaffe, GJ | 2 |
| Yang, CS | 1 |
| Khawly, JA | 1 |
| Hainsworth, DP | 1 |
| Chen, SN | 1 |
| Guo, H | 1 |
| Kon, CH | 2 |
| Occleston, NL | 1 |
| Foss, A | 1 |
| Sheridan, C | 1 |
| Khaw, PT | 2 |
| Tung, IC | 1 |
| Wu, WC | 1 |
| Kao, YH | 1 |
| Chang, YC | 1 |
| Chung, CH | 1 |
| Hu, DN | 1 |
| Allinson, RW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.[NCT02834559] | Phase 3 | 326 participants (Actual) | Interventional | 2016-10-27 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for fluorouracil and Proliferative Vitreoretinopathy
| Article | Year |
|---|---|
Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery.
Topics: Fluorouracil; Heparin, Low-Molecular-Weight; Humans; Intravitreal Injections; Postoperative Complica | 2013 |
[Proliferative vitreoretinopathy: prophylactic treatment].
Topics: Antibiotics, Antineoplastic; Colchicine; Daunorubicin; Fibrinolytic Agents; Fluorouracil; Glucocorti | 2014 |
Clinical management of proliferative vitreoretinopathy: an update.
Topics: Anti-Inflammatory Agents; Endotamponade; Fluorouracil; Heparin, Low-Molecular-Weight; Humans; Immuno | 2015 |
Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery.
Topics: Fluorouracil; Heparin, Low-Molecular-Weight; Humans; Injections, Intraocular; Postoperative Complica | 2010 |
Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside.
Topics: Animals; Clinical Trials as Topic; Daunorubicin; Fluorouracil; Heparin, Low-Molecular-Weight; Humans | 2012 |
7 trials available for fluorouracil and Proliferative Vitreoretinopathy
| Article | Year |
|---|---|
Intravitreal 5-Fluorouracil and Heparin to Prevent Proliferative Vitreoretinopathy: Results from a Randomized Clinical Trial.
Topics: Dalteparin; Double-Blind Method; Fluorouracil; Heparin; Heparin, Low-Molecular-Weight; Humans; Retin | 2022 |
Re: Schaub et al.: Intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy: results from a randomized clinical trial (Ophthalmology. 2022;129:1129-1141).
Topics: Fluorouracil; Heparin; Humans; Retinal Detachment; Vitreoretinopathy, Proliferative | 2023 |
Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial.
Topics: Data Interpretation, Statistical; Double-Blind Method; Endpoint Determination; Fluorouracil; Heparin | 2018 |
Retinal detachment repair by vitrectomy: simplified formulae to estimate the risk of failure.
Topics: Adult; Aged; Antimetabolites; Female; Fibrinolytic Agents; Fluorouracil; Follow-Up Studies; Heparin, | 2011 |
A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy.
Topics: Aged; Antimetabolites; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; | 2004 |
[Prevention of proliferative vitreoretinopathy using 5-FU heparin: clinical tolerance and efficacy].
Topics: Drug Therapy, Combination; Female; Fluorouracil; Heparin; Humans; Male; Middle Aged; Prospective Stu | 2005 |
Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Female; | 2001 |
16 other studies available for fluorouracil and Proliferative Vitreoretinopathy
| Article | Year |
|---|---|
Self-assembling hydrogel loaded with 5-FU PLGA microspheres as a novel vitreous substitute for proliferative vitreoretinopathy.
Topics: Animals; Cell Line; Drug Delivery Systems; Fluorouracil; Humans; Hydrogels; Microspheres; Rabbits; V | 2020 |
Comparative cytotoxic and antiproliferative profile of methotrexate and fluorouracil on different ocular cells.
Topics: Apoptosis; Cells, Cultured; Fluorouracil; Humans; Immunosuppressive Agents; Methotrexate; Retinal Pi | 2021 |
Evaluation of 5-fluorouracil released from a foldable capsular vitreous body in vitro and in vivo.
Topics: Animals; Antimetabolites; Aqueous Humor; Biological Availability; Chromatography, High Pressure Liqu | 2012 |
Fluorouracil prodrugs for the treatment of proliferative vitreoretinopathy: formulation in silicone oil and in vitro release of fluorouracil.
Topics: Chemistry, Pharmaceutical; Drug Stability; Fluorouracil; Kinetics; Magnetic Resonance Spectroscopy; | 2003 |
Case selection in macular relocation surgery for age related macular degeneration.
Topics: Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Choroidal Neovascularization; Fluorouracil; Follow- | 2004 |
An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biodegradation, Environmental; Disease Models, Ani | 2004 |
[Efficacy of 5-fluorouracil polyactic acid microsphere in prevention of proliferative vitreoretinopathy].
Topics: Animals; Antimetabolites; Delayed-Action Preparations; Fluorouracil; Lactates; Microspheres; Rabbits | 2006 |
Systemic absorption of 5-fluorouracil during vitrectomy.
Topics: Absorption; Antimetabolites; beta-Alanine; Fluorouracil; Gas Chromatography-Mass Spectrometry; Human | 2006 |
Systemic resorption of 5-fluorouracil used in infusion fluid during vitrectomy.
Topics: Absorption; Fluorouracil; Humans; Vitrectomy; Vitreoretinopathy, Proliferative | 2007 |
Suppression of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU.
Topics: Animals; Antimetabolites; Biocompatible Materials; Biodegradation, Environmental; Delayed-Action Pre | 1995 |
Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy.
Topics: Animals; Antimetabolites; Delayed-Action Preparations; Dexamethasone; Disease Models, Animal; Drug C | 1996 |
An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy.
Topics: Animals; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Disease Models, Animal; | 1998 |
Effects of single, short-term exposures of human retinal pigment epithelial cells to thiotepa or 5-fluorouracil: implications for the treatment of proliferative vitreoretinopathy.
Topics: Alkylating Agents; Antimetabolites; Cell Culture Techniques; Cell Division; Cell Survival; Collagen; | 1998 |
Shaken not stirred.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Fluorouracil; Heparin, Low-Molecular-Weight; Hu | 2001 |
The effect of combined 5-fluorouracil and dexamethasone on cultured human retinal pigment epithelial cells.
Topics: Cell Division; Cells, Cultured; Dexamethasone; Dose-Response Relationship, Drug; Drug Synergism; Flu | 2001 |
Adjuvant 5-FU and heparin prevent PVR.
Topics: Chemotherapy, Adjuvant; Drug Therapy, Combination; Fluorouracil; Heparin, Low-Molecular-Weight; Huma | 2002 |